VITAL THERAPIES WKN: A2PHD4 ISIN: US4525EP1011 Kürzel: IMUX Forum: Aktien Thema: Hauptdiskussion
1,00 EUR
-0,99 %-0,01
16. Nov, 13:00:56 Uhr,
Lang & Schwarz
Kommentare 6.539
Katzenzombie,
05.01.2024 12:49 Uhr
1
Meine Alerts sind gerade alle gefallen. Was ist das denn…? Hält das überhaupt bis 15.30 h? Hat jemand vertiefende Infos?
Katzenzombie,
05.01.2024 12:54 Uhr
0
NEW YORK, Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu thereof) in a three-tranche offering.
The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions. The second tranche is a mandatory purchase of an additional $80 million of shares of common stock (or pre-funded warrants) at $1.716 per share, representing 120% of the first tranche purchase price and is conditioned on the announcement of phase 2b topline data for the Company's vidofludimus calcium (IMU-838) progressive multiple sclerosis clinical trial, volume weighted average share price levels, and minimum trading volumes. A third tranche, to occur no later than three years after the second tranche, provides for the issuance of $80 million of shares of common stock (or pre-funded warrants in lieu thereof) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a "cashless" or net settlement basis, which would reduce the proceeds to be raised in the financing. The third tranche is conditioned on the same volume weighted average share price levels and minimum trading volumes as the second tranche. Assuming that the second tranche is exercised, and depending on the extent to which the investors elect to fund the third tranche through a net settlement basis, total gross proceeds from the offering to the Company would be between $160 and $240 million.
JoSu123,
05.01.2024 12:48 Uhr
0
Denkt dran Gewinne mitnehmen. Wird denke ich spätestens heute nachmittag Abverkäufe geben.
ETon,
05.01.2024 12:47 Uhr
0
Niemand hat so viel Pech wie ich. Wäre ich investiert wäre der niemals so gestiegen....
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | NVIDIA Hauptdiskussion | +0,70 % | |
2 | Exela 2023 sachliches Forum | +5,36 % | |
3 | MicroStrategy | +0,43 % | |
4 | Goldpreis Hauptdiskussion | ±0,00 % | |
5 | Trading- und Aktien-Chat | ||
6 | Lilium Aktie | -42,62 % | |
7 | DAX Hauptdiskussion | +0,09 % | |
8 | APPLE Hauptdiskussion | +0,05 % | |
9 | Börsen Comedy | ||
10 | BTC/USD Hauptdiskussion | +1,59 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | NVIDIA Hauptdiskussion | +0,70 % | |
2 | MicroStrategy | +0,43 % | |
3 | Exela 2023 sachliches Forum | +5,36 % | |
4 | Lilium Aktie | -42,62 % | |
5 | MODERNA INC. DL-,0001 Hauptdiskussion | +0,63 % | |
6 | Nio für normale Kommunikation | ±0,00 % | |
7 | APPLE Hauptdiskussion | +0,05 % | |
8 | BioNTech Hauptdiskussion | -0,08 % | |
9 | VARTA Hauptdiskussion | ±0,00 % | |
10 | Blockmate | -0,63 % | Alle Diskussionen |